Uncategorised - European Medical Journal

SDS Toothpaste Affects Oesophageal Barrier Function

An exploratory human study found SDS-containing toothpaste reduced oesophageal mucosal impedance and altered salivary properties after brushing.

Alexithymia Linked to Poorer Quality of Life in Anaphylaxis

Alexithymia Linked to Poorer Quality of Life in Anaphylaxis

A study suggests alexithymia is associated with poorer quality of life and greater psychological burden in adults living with anaphylaxis.

Fluid Choice Does Not Change Paediatric Sepsis Outcomes

Balanced fluid did not reduce major adverse kidney events compared with saline in children treated for septic shock.

40% of Ovarian Cancers Diagnosed After Emergency Hospital Admission

Two in every five women diagnosed with ovarian cancer in England are diagnosed only after emergency hospital admission.

Two New Tests Could Help GPs Diagnose Endometriosis Faster

Two New Tests Could Help GPs Diagnose Endometriosis Faster

Two new non-invasive technologies could help cut waiting times for primary care endometriosis diagnoses in the UK.

How Posture Shifts Ventilation Across Healthy Lungs

Body position reshapes ventilation distribution in healthy lungs, with lateral positioning producing the strongest gravity-dependent shifts.

Quickfire Q&A: Roberto Mina

Roberto Mina shares insights from EHA 2026 on MonumenTAL-3, MajesTEC-9, CEPHEUS, and the evolving multiple myeloma treatment landscape.

Obesity and Metabolic Multimorbidity Burden Reveal Hidden Health Risks[

Obesity and Metabolic Multimorbidity Burden Reveal Hidden Health Risks

A survey-based Metabolic Multimorbidity Burden Index identified substantial differences in health risk beyond body mass index, with high burden linked to poorer health outcomes.

EMJ shortlisted for Marketing Week Awards 2026

EMJ has been named a finalist in the Excellence in Health and Life Sciences category for its work with PARI Pharma GmbH.

Merck wins FDA nod for enlicitide oral cholesterol pill

Merck’s enlicitide has received FDA approval as the first oral PCSK9 inhibitor for lowering LDL-C in adults with hypercholesterolemia.